166 related articles for article (PubMed ID: 25413190)
1. Safety of sorafenib therapy in elderly adults with advanced hepatocellular carcinoma.
Francini E; Mazzaroppi S; Fiaschi AI; Petrioli R; Laera L; Roviello G; Pira T; Pellicelli AM; Bianco V
J Am Geriatr Soc; 2014 Nov; 62(11):2204-5. PubMed ID: 25413190
[No Abstract] [Full Text] [Related]
2. A case of reversible cardiomyopathy associated with sorafenib in advanced hepatocellular carcinoma.
Park H; Han SH; Kang H; Park K
Int J Cardiol; 2012 Sep; 160(1):e10-1. PubMed ID: 22289299
[No Abstract] [Full Text] [Related]
3. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase III trial.
Bruix J; Raoul JL; Sherman M; Mazzaferro V; Bolondi L; Craxi A; Galle PR; Santoro A; Beaugrand M; Sangiovanni A; Porta C; Gerken G; Marrero JA; Nadel A; Shan M; Moscovici M; Voliotis D; Llovet JM
J Hepatol; 2012 Oct; 57(4):821-9. PubMed ID: 22727733
[TBL] [Abstract][Full Text] [Related]
4. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma.
Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC
Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249
[TBL] [Abstract][Full Text] [Related]
5. Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma.
Santini D; Addeo R; Vincenzi B; Calvieri A; Montella L; Silletta M; Caraglia M; Vespasiani U; Picardi A; Del Prete S; Tonini G
Expert Rev Anticancer Ther; 2012 Oct; 12(10):1283-8. PubMed ID: 23094801
[TBL] [Abstract][Full Text] [Related]
6. Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.
Di Costanzo GG; de Stefano G; Tortora R; Farella N; Addario L; Lampasi F; Lanza AG; Cordone G; Imparato M; Caporaso N
Future Oncol; 2015; 11(6):943-51. PubMed ID: 25760975
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib use in elderly patients with hepatocellular carcinoma: caution about use of platelet aggregation inhibitors.
Edeline J; Crouzet L; Le Sourd S; Larible C; Brunot A; Le Roy F; Cattenoz C; Latournerie M; Gédouin D; Guillygomarc'h A; Boucher E
Cancer Chemother Pharmacol; 2015 Jan; 75(1):215-9. PubMed ID: 25477009
[TBL] [Abstract][Full Text] [Related]
8. Sorafenib: the gold standard therapy in advanced hepatocellular carcinoma and beyond.
Gadaleta-Caldarola G; Divella R; Mazzocca A; Infusino S; Ferraro E; Filippelli G; Daniele A; Sabbà C; Abbate I; Brandi M
Future Oncol; 2015; 11(16):2263-6. PubMed ID: 26260805
[No Abstract] [Full Text] [Related]
9. [Metastatic adrenal necrosis under sorafenib treatment for hepatocellular carcinoma].
Fabries P; Pauleau G; Brardjanian S; Artéaga C; Guisset M; Coton T
Presse Med; 2013 Feb; 42(2):235-7. PubMed ID: 22425476
[No Abstract] [Full Text] [Related]
10. Hepatocellular carcinoma treated by sorafenib with complete radiological response according to mRECIST criteria: could we stop the treatment? About four cases.
Poullenot F; Bioulac-Sage P; Laumonier H; Saric J; Carteret T; Blanc JF
Acta Oncol; 2014 Mar; 53(3):420-3. PubMed ID: 23713857
[No Abstract] [Full Text] [Related]
11. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
Jia N; Liou I; Halldorson J; Carithers R; Perkins J; Reyes J; Yeh M; Stohr E; Rao S; Lin EH
Anticancer Res; 2013 Jun; 33(6):2797-800. PubMed ID: 23749944
[TBL] [Abstract][Full Text] [Related]
12. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
13. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study.
Johnson PJ; Qin S; Park JW; Poon RT; Raoul JL; Philip PA; Hsu CH; Hu TH; Heo J; Xu J; Lu L; Chao Y; Boucher E; Han KH; Paik SW; Robles-Aviña J; Kudo M; Yan L; Sobhonslidsuk A; Komov D; Decaens T; Tak WY; Jeng LB; Liu D; Ezzeddine R; Walters I; Cheng AL
J Clin Oncol; 2013 Oct; 31(28):3517-24. PubMed ID: 23980084
[TBL] [Abstract][Full Text] [Related]
14. Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability.
Yoon EL; Yeon JE; Lee HJ; Suh SJ; Lee SJ; Kang SH; Kang K; Yoo YJ; Kim JH; Yim HJ; Byun KS
J Clin Gastroenterol; 2014 Mar; 48(3):e22-9. PubMed ID: 24045282
[TBL] [Abstract][Full Text] [Related]
15. Complete Response to Full-Dose Sorafenib Treatment in an Elderly HCC Patient: a Case Report.
de Stefano G; Iodice V; Farella N
J Gastrointest Cancer; 2015 Dec; 46(4):430-3. PubMed ID: 25894635
[No Abstract] [Full Text] [Related]
16. Treatment of intermediate-stage hepatocellular carcinoma.
Finn RS
Clin Adv Hematol Oncol; 2015 Aug; 13(8):501-3. PubMed ID: 26351811
[No Abstract] [Full Text] [Related]
17. Sorafenib-associated psoriasiform eruption in a patient with hepatocellular carcinoma.
İlknur T; Akarsu S; Çarsanbali S; Lebe B; Fetil E
J Drugs Dermatol; 2014 Aug; 13(8):899-900. PubMed ID: 25116964
[No Abstract] [Full Text] [Related]
18. [Current status and future perspective of sorafenib for advanced hepatocellular carcinoma].
Ikeda M; Mitsunaga S; Shimizu S; Ohno I; Takahashi H; Okuyama H; Kuwahara A; Okusaka T
Nihon Shokakibyo Gakkai Zasshi; 2012 Aug; 109(8):1346-54. PubMed ID: 22863957
[No Abstract] [Full Text] [Related]
19. Learning from 7 Years of Experience with Sorafenib in Advanced HCC: Sorafenib Better than Sorafenib?
Faivre S; de Gramont A; Raymond E
Target Oncol; 2016 Aug; 11(4):565-7. PubMed ID: 26996978
[No Abstract] [Full Text] [Related]
20. Prognostic factors in patients with hepatocellular carcinoma refractory or intolerant to sorafenib.
Okuyama H; Ikeda M; Kuwahara A; Takahashi H; Ohno I; Shimizu S; Mitsunaga S; Senda S; Okusaka T
Oncology; 2015; 88(4):241-6. PubMed ID: 25503567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]